Dynavax Technologies (NASDAQ:DVAX) Upgraded to "Buy" at StockNews.com

StockNews.com upgraded shares of Dynavax Technologies (NASDAQ:DVAX - Free Report) from a hold rating to a buy rating in a report issued on Monday morning.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a report on Friday, February 21st. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, The Goldman Sachs Group lowered Dynavax Technologies from a "neutral" rating to a "sell" rating and reduced their price target for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th.

Dynavax Technologies Stock Performance

DVAX traded up $0.28 during trading on Monday, reaching $13.69. 2,211,668 shares of the company were exchanged, compared to its average volume of 1,852,245. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $14.05. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The firm has a 50 day moving average of $12.84 and a 200 day moving average of $12.07. The stock has a market cap of $1.80 billion, a P/E ratio of 76.06 and a beta of 1.32.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. The business had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. On average, sell-side analysts forecast that Dynavax Technologies will post 0.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. E Fund Management Co. Ltd. lifted its position in Dynavax Technologies by 4.6% in the fourth quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company's stock worth $225,000 after purchasing an additional 771 shares during the period. Summit Investment Advisors Inc. lifted its holdings in shares of Dynavax Technologies by 7.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company's stock valued at $176,000 after buying an additional 904 shares during the period. Nisa Investment Advisors LLC boosted its stake in Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after buying an additional 1,076 shares in the last quarter. Sanctuary Advisors LLC grew its holdings in Dynavax Technologies by 6.3% during the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company's stock worth $245,000 after acquiring an additional 1,109 shares during the period. Finally, Russell Investments Group Ltd. raised its position in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.